tbuckley/cabot-search huggingface dataset:
Pilot study of probe-based confocal laser endomicroscopy during colonoscopic surveillance of patients with longstanding ulcerative colitis
Authors: F. van den Broek, J. van Es, S. van Eeden, P. Stokkers, C. Ponsioen, J. Reitsma, P. Fockens, E. Dekker
Journal: Endoscopy (2010)

Surveillance of patients with ulcerative colitis consists of taking targeted and random biopsies, which is time-consuming and of doubtful efficiency. The use of probe-based confocal laser endomicroscopy (pCLE) may increase efficiency. This prospective pilot study aimed to evaluate the feasibility and diagnostic accuracy of pCLE in ulcerative colitis surveillance.In 22 patients with ulcerative colitis, 48 visible lesions and 87 random areas were initially evaluated by real-time narrow-band imaging (NBI) and high-definition endoscopy (HDE). Before taking biopsies, fluorescein-enhanced pCLE was performed. All pCLE videos were scored afterwards by two endoscopists who were blinded to histology and endoscopy. Outcome measures were: (1) the feasibility of pCLE, expressed as pCLE imaging time required, percentage of imaging time with clear pCLE histology, and pCLE video quality as rated by two endoscopists; and (2) the diagnostic accuracy of pCLE.The median pCLE imaging time required was 98 seconds for lesions vs. 66 seconds for random areas ( P = 0.002). The median percentages of imaging time with clear pCLE histology were 61 % vs. 81 % respectively ( P < 0.001). The pCLE video quality was rated as good/excellent in 69 %. Feasibility was significantly poorer for sessile and pedunculated mobile lesions. The sensitivity, specificity, and accuracy of blinded pCLE were 65 %, 82 %, and 81 %, whereas these figures were 100 %, 89 %, and 92 % for real-time endoscopic diagnosis with NBI and HDE.This study demonstrates that pCLE for ulcerative colitis surveillance is feasible with reasonable diagnostic accuracy. Future research should show whether increased experience with pCLE improves its ease of use and whether real-time pCLE diagnosis is associated with greater diagnostic accuracy.
AB0513 (F) good outcomes at week 24 is lead by early introduction of tocilizumab and favorable treatment response up to week 12
Authors: A. Oguma, S. Takahashi, T. Sawabe
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Tocilizumab (TCZ) is a biological product approved as a treatment for rheumatoid arthritis. The REACTION 52-week study reported that baseline HAQ is a predictive factor of clinical, functional and structural remission at one year of treatment. <h3>Objectives</h3> To investigate clinical and functional remission rates at Week 24 of TCZ treatment for rheumatoid arthritis as well as factors that contribute to the achievement of clinical and functional remission. <h3>Methods</h3> This study evaluated 40 patients followed up for at least 24 weeks after the initiation of TCZ treatment. Patient demographic data: mean age, 62.9±11.7years; mean disease duration, 10.8±11.9years; CDAI, 19.6±11.7; m-HAQ, 0.6±0.6; concomitant use of MTX, 75% (30/40); mean MTX dose, 7.4±2.2 mg/week; and prior use of TNF inhibitors, 40% (16/40). CDAI and m-HAQ were used to evaluate clinical and functional efficacy (LOCF method), and factors that contribute to clinical and functional remission at Week 24 were also investigated. <h3>Results</h3> At Week 24, tocilizumab were continued in 34 patients (85.0%). One patient had discontinued tocilizumab because of diverticular hemorrhage. No other serious adverse events were observed. CDAI was significantly improved to 6.3±8.1 (<i>P</i>&lt;0.01), with a clinical remission rate (CDAI≤2.8) of 47.5% and a Boolean remission rate of 40.0%. At Week 24, m-HAQ was significantly improved to 0.4±0.5 (<i>P</i>&lt;0.05), with a functional remission rate (m-HAQ≤0.5) of 67.5%. The clinical and functional remission rate (CDAI≤2.8 + m-HAQ≤0.5) at Week 24 was 40.0%, and the factors that contribute to this rate identified by univariate analysis included: younger age at baseline (<i>P</i>&lt;0.01), lower patient global VAS scores (<i>P</i>&lt;0.05), lower m-HAQ (<i>P</i>&lt;0.05), achievement of DAS-28-ESR remission at Week 12 (<i>P</i>&lt;0.05), and achievement of Boolean remission at Weeks 4 and 12 (<i>P</i>&lt;0.05 and <i>P</i>&lt;0.01, respectively). <h3>Conclusions</h3> This study suggests that early introduction of TCZ before worsening of functional disorder is necessary to achieve good outcomes at Week 24 of TCZ treatment. Favorable treatment response up to Week 12 is considered to be a predictive factor of good outcomes. <h3>References</h3> T.Takeuchi et.al, Clinical,radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study. Rheumatology 2011.50(10):1908-15 <h3>Disclosure of Interest</h3> None Declared
Definition, aims, and implementation of <scp>GA</scp><sup>2</sup><scp>LEN</scp> Urticaria Centers of Reference and Excellence
Authors: M. Maurer, M. Metz, C. Bindslev‐Jensen, J. Bousquet, G. W. Canonica, M. K. Church, K. V. Godse, C. E. Grattan, M. Hide, E. Kocatürk, M. Magerl, M. Makris, R. Meshkova, S. S. Saini, G. Sussman, E. Toubi, Z. Zhao, T. Zuberbier, A. Gimenez‐Arnau
Journal: Allergy (2016)

Abstract Background GA² LEN , the Global Allergy and Asthma European Network, has recently launched a program for the development, interaction, and accreditation of centers of reference and excellence in special areas of allergy embedded in its overall quality management of allergy centers of excellence. The first area chosen is urticaria. Urticaria is a common and debilitating condition and can be a challenge for both patients and treating physicians, especially when chronic. Centers of reference and excellence in urticaria ( UCARE s) can help to improve the management of hard‐to‐treat conditions such as urticaria. Aims Here, we describe the aims, the requirements and deliverables, the application process, and the audit and accreditation protocol for GA ² LEN UCARE s. Results The main aims of GA ² LEN UCARE s are to provide excellence in urticaria management, to increase the knowledge of urticaria by research and education, and to promote the awareness of urticaria by advocacy activities. To become a certified GA ² LEN UCARE , urticaria centers have to apply and fulfill 32 requirements, defined by specific deliverables that are assessed during an audit visit. Discussion and Conclusion The GA ² LEN UCARE program will result in a strong network of urticaria specialists, promote urticaria research, and harmonize and improve urticaria management globally.
A memorable patient: Unerring trust
Authors: D. A Black
Journal: BMJ (1999)

Mine is a rural practice in north Yorkshire, spanning over 20 villages. Needless to say, we have several branch surgeries, each of which has a different social grouping and a character of its own. Close to one distant surgery was a piece of common land, much favoured by the travelling people, most of them genuine Romany.

When in residence, they would turn up at the surgery in hordes, very demanding, but always respectful and polite. You had the feeling that complaints and illnesses had been “stored up,” for a good sorting out. They always attended surgery and never called me out, although I had once been escorted with great dignity to a stream, in order to wash after delivering a baby.

I was, therefore, surprised to be asked to call at the caravans in order to see a man who was “very sick.” It was a summer evening and a chair was produced for me to sit in the open. A cyanosed and breathless man of about 65 was helped from a caravan in obvious cor pulmonale. Accustomed to a different audience, I was horrified and began to talk about hospital admission, but this was firmly and politely declined.

At the end of a long day I became irritated and asked if they had brought me seven miles to refuse my advice. With patience they explained that they had received my advice. If I thought he was going to die then they were sure I was correct. Politely they added, “What you don’t realise is, we have brought him from 200 miles away to see you.”

Humbled I returned to my comfortable home. I never saw him again.
The Use of Aspirin in Ischemic Heart Disease
Authors: Jane F. Desforges, John E. Willard, Richard A. Lange, L. David Hillis
Journal: New England Journal of Medicine (1992)

WITHIN a decade of the isolation of salicylate in 1892, aspirin was introduced as an analgesic and antipyretic agent. In 1971, Vane described its inhibition of prostaglandin synthesis from arachidonate in homogenates of guinea pig lung,1 and Smith and Willis demonstrated that aspirin blocks the production of prostaglandin in human platelets.2 During the past decade, it has been shown that platelet aggregation and the formation of thrombi are pathophysiologically important in syndromes of ischemic heart disease. As a result, aspirin is widely used in patients with ischemic heart disease, and its use has recently been advocated in subjects without clinically . . .
AB1138-HPR Systemic Adverse Events in A Cohort of Patients with Rheumatoid Arthritis Using BIOLOGICS in A Real-Life Setting
Authors: A. Palomino, V. Giraldo, G. Saavedra-Martinez, L. Villarreal, A. Tique, D. Gomez, J. Bello-Gualtero, F. Salas, P. Santos-Moreno
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Biological therapy is a major therapeutic tool to prevent clinical and radiological progression of rheumatoid arthritis (RA). On the other hand, adverse effects of these medications are a problem in clinical practice. <h3>Objectives</h3> The aim of this study was to describe and compare the most frequent adverse events with the use of biologic therapy in patients with RA in a real-life ambulatory setting. <h3>Methods</h3> A descriptive study was done by nursing service. A review of adverse event reports presented in pharmacovigilance committee was completed monthly during last 36 months in a specialized in RA center in Colombia. Descriptive epidemiology was used, percentages and averages were calculated. <h3>Results</h3> 570 patients were using biological therapy in a cohort of 2214 RA patients last 36 months. Were 490 women (85.9%) and 80 (14.0%) men. Mean age 60.7 years old. In 163 (28.5% of all) patients were reported adverse events (AE); AE were categorized according WHO classification in mild, moderate and severe; between them 59 (36.2%) were mild, 97 (59.5%) were moderate and 7 (4.2%) were severe. From 163 AE reported, 86 (52.7%) were systemic and 77 (47.2%) dermatologic reactions. Regarding therapeutic approach in 63 patients (38.6%) biologic was temporarily suspended, in 57 (34.9%) was permanently withdrawn and patients switched to another biological, and 43 (26.3%) patients were followed for drug and reactions surveillance. Concerning to type of biologic in 120 patients (73.6%) AE were with anti-TNF therapies. <h3>Conclusions</h3> AE using biologics documented in patients of a specialized RA center are similar to those reported in literature; Biological therapy is considered a safe and recommended treatment for management of RA. AE were more common with anti-TNFs therapies. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.5438
Harnessing clinical solving abilities through safety reporting to drive quality improvement in the NHS
Authors: A.-M. Howell, G. Bouras, E. M. Burns
Journal: BMJ (2013)

Don Berwick presents a welcome and measured view on NHS workers who face increasing scrutiny over their ability to deliver high quality, safe healthcare. His latest report, insightfully distilled by McKee,1 recognises that the challenges faced are not unique to the UK and that blame must be diverted from those who flag safety concerns.

Much emphasis has been placed on increasing transparency and accountability. The Danes …
Can Concurrent Chemo-Radiation Be Delayed by Induction Chemotherapy in the Curative Treatment of Stage Iii Non-Small Cell Lung Carcinoma? a Pooled Analysis
Authors: C. Guilbault, A. Garant, M. Almajed, S. Faria, S. Owen, M. Duclos, L. Ofiara, J. Gruber, V. Hirsh, N. Kopek
Journal: Annals of Oncology (2015)
Small Lung Cancer Demonstrated With Tc-99m Tetrofosmin Imaging
Authors: Eiji Ohtake, Tsutomu Fukuda, Hideyuki Hasegawa, Yasuhiro Kido
Journal: Clinical Nuclear Medicine (1996)

A small lung cancer in a 65-year-old man was clearly demonstrated by Tc-99m tetrofosmin, which was developed for myocardial perfusion imaging. The lesion was obscure on plain x-ray and was depicted as a faint area situated in the superior segment of the left lower lobe on CT image. Left lower lobectomy was performed and the pathologic examination revealed it to be an adenocarcinoma of 3 cm × 2.5 cm × 1 cm in size.
Feasible Socialism: The National Health Service Past, Present and Future
Authors: G. D. Smith
Journal: BMJ (1995)

Julian Tudor Hart Socialist Health Association, pounds sterling6, pp 112 ISBN 0 900687 24 X

As the march of the NHS reforms continues and it increasingly looks as though Tony Blair's “New Labour party”—basically the old (pre-Thatcher) Tory party—will do little to reverse the process, Julian Tudor Hart dares to declare that the emperor has no clothes.

Having learnt that if nonsense is repeated often enough it becomes common knowledge, advocates of the reforms suggest that the NHS had become a bloated bureaucracy, with too much money spent on administration and too little on patient care. The British system, however, has been considerably cheaper, in terms of the percentage of gross national product it consumes, than competition based systems elsewhere. The reforms threaten to remove this advantage as expenditure …
The Antihypertensive Effects of Fish Oil
Authors: Howard R. Knapp, Garret A. FitzGerald
Journal: New England Journal of Medicine (1989)

Both n–3 and n–6 polyunsaturated fats have been suggested to lower blood pressure, an effect ascribed to altered biosynthesis of eicosanoids. To test these hypotheses, we studied blood pressure and eicosanoid production during supplementation of dietary fat for four weeks in 32 men with mild essential hypertension. Supplementation was preceded and followed by four-week run-in and recovery periods. Groups of eight subjects received either 10 ml or 50 ml of fish oil (3 or 15 g of n–3 fatty acids) daily, 50 ml of safflower oil (39 g of n–6 fatty acids), or 50 ml of a mixture of oils that approximated the types of fat present in the American diet. The biosynthesis of eicosanoids was assessed by the measurement of urinary metabolites. Blood pressure decreased in the men who received the high dose of fish oil (systolic pressure by a mean of 6.5 mm Hg [P<0.03] and diastolic pressure by 4.4 mm Hg [P<0.015]), but not in the other groups. Although the formation of vasodilatory prostacyclins (prostaglandins I2 and I3) increased initially, this increase was not maintained as blood pressure fell. The level of THROMBOXANE A2 metabolites fell; metabolites of thromboxane A3 were detected in the groups receiving fish oil. The formation of prostaglandin E2 increased during supplementation with safflower oil and tended to decrease with fish oil; no prostaglandin E3 metabolite was detected. Our data indicate that high doses of fish oil can reduce blood pressure in men with essential hypertension. However, the clinical usefulness and safety of fish oil in the treatment of hypertension will require further study. (N Engl J Med 1989; 320:1037–43.)
Abstract 4717: A search for overlapping HLA risk loci between NHL and autoimmune diseases
Authors: Lucia Conde, Paige M. Bracci, Martin T. Smith, Nicholas K. Akers, Jacques Riby, Luz Agana, Elizabeth A. Holly, Eran Halperin, Christine F. Skibola
Journal: Cancer Research (2010)

Abstract Non-Hodgkin lymphoma (NHL) is a group of B- and T-cell neoplasms originating primarily from the lymph nodes, and represents the most common hematological malignancy in the United States. We recently conducted a genome-wide association study (GWAS) using DNA pools and identified a new risk locus for follicular lymphoma (FL) in the Class 1 human leukocyte antigen (HLA) region on chromosome 6. Currently, we are following up these results in a second GWAS using a subset of 757 NHL cases and 811 controls from a larger case-control study of NHL based in the San Francisco Bay Area using the Illumina HumanCNV370-Duo BeadChip. In the preliminary scan, we found additional evidence of Class 1 HLA loci that influence FL susceptibility, as well as loci in the Class 2 region, suggesting the importance of HLA genetic variation in FL risk. There is also clear evidence that HLA Class 1 and Class 2 loci confer genetic susceptibility to autoimmune diseases such as Crohn's disease (CD), type 1 diabetes (T1D), rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Thus, because a history of autoimmune disease may increase risk of NHL, we explored whether HLA-region risk loci are common between these autoimmune diseases and NHL. Using genetic data available from the Wellcome Trust Case-Control Consortium (WTCCC) for CD and the software package BEAGLE 3.0.3, we imputed SNPs to look for association signals in the HLA region. SNPs were imputed based on CD genotyped SNPs and haplotype information from unrelated CEU samples in the HapMap phase II data. A Cochran-Armitage test for an additive genetic effect implemented in PLINK v1.05 was subsequently performed to test the genotype-phenotype associations of genotyped and imputed SNPs. Our preliminary results suggest associations in the HLA Class 2 region near the HLA-DQA2 and HLA-DQB2 genes, providing evidence that overlapping risk loci may exist between FL and CD. We are currently expanding our analysis to include genetic data for other autoimmune diseases available from WTCCC such as T1D and RA. These analyses will contribute new data about genetic variation in plausible HLA region pathways and will help to identify potentially functional genetic factors that contribute to lymphoma susceptibility. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 4717.
Abstract P2-09-02: Validation of a Novel Staging System for Disease-Specific Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Authors: EA Mittendorf, JS Jeruss, SL Tucker, A Kolli, LA Newman, AM Gonzalez-Angulo, TA Buchholz, AA Sahin, JN Cormier, A Buzdar, GN Hortobagyi, KK. Hunt
Journal: Cancer Research (2010)

Abstract Purpose We previously described a novel breast cancer staging system for assessing prognosis after neoadjuvant chemotherapy based on pretreatment clinical stage (CS), estrogen receptor status (E), grade (G) and post-treatment pathologic stage (PS). This CPS+EG staging system assigned and summed points for each factor, allowing for better determination of breast cancer-specific survival than CS or PS alone. The current study was undertaken to validate this staging system using internal and external cohorts. Methods We identified 804 patients treated with neoadjuvant chemotherapy at our institution from 2003-2005 who were not part of the original determination of the CPS+EG staging system and an external cohort of 165 patients treated at another institution. Clinicopathologic characteristics, treatment regimens, and patient outcomes were assessed. Outcomes were stratified by CPS+EG score in order to test whether the 5-year disease-specific survival (DSS) in each CPS+EG group was numerically as predicted. Results The 5-year DSS for the internal cohort was 77% (95% CI: 72-82) at a median follow-up of 3.4 years (range, 03-5.9). The 5-year DSS for the external cohort was 86% (95% CI: 7 -91) at a median follow-up of 4.7 years (range, 0.5-10.5). The ability of the CPS+EG score to distinguish outcomes based on good or poor prognosis was confirmed in both the internal and external cohorts. In both cohorts, application of the CPS+EG staging system facilitated more accurate categorization of patients into prognostic subgroups than CS or final PS as defined by the American Joint Committee on Cancer (AJCC) staging system. Disease-Specific Survival Outcomes Based on the CPS+EG Staging System Application of the CPS+EG to all three cohorts combined, demonstrated 5-year DSS ranging from 23% to 99% versus 5-year DSS ranging from 61% to 92% based on presenting CS or 58% to 95% based on post-treatment PS. Conclusion The current study validates the CPS+EG staging system in independent patient cohorts. We recommend that biologic markers and response to treatment be incorporated into revised versions of the AJCC staging system for patients receiving neoadjuvant chemotherapy. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P2-09-02.
Stromal cell-independent differentiation of human cord blood CD34+CD38− lymphohematopoietic progenitors toward B cell lineage
Authors: Y Yoshikawa, F Hirayama, M Kanai, S Nakajo, J Ohkawara, M Fujihara, M Yamaguchi, N Sato, M Kasai, S Sekiguchi, K Ikebuchi
Journal: Leukemia (2000)
Efficacy of Reslizumab in Older Patients (≥65 years) with Asthma and Elevated Blood Eosinophils: Results from a Pooled Analysis of Two Phase 3, Placebo-Controlled Trials
Authors: David I. Bernstein, Lyndon Mansfield, James Zangrilli, Margaret Garin
Journal: Journal of Allergy and Clinical Immunology (2016)